HER-2 Positive Breast Cancer - a Mini-Review

Abstract

Currently, cancers are leading cause of death all over the world (Saber et al., 2015). Breast cancer is one of among all with increased incidence, high mortality rate, and high economic and social costs (Zainal et al., 2013). It is the most common type of cancer among females worldwide (Cetin et al., 2014).Breast cancer is actually the uncontrolled proliferation of cells which starts in breast cells and attains malignancy. Recently it has shown that breast cancer contributes 11% among all types of cancer diagnosed globally annually and it is one of the leading cause of death among women (Majeed et al., 2014). All women regardless of of their racial or ethnic origin or heritage are at risk of breast cancer (Asif et al., 2014). Approximately 1.7 million Women were diagnosed with breast cancer in 2012. It is the most frequently diagnosed cancer among women in 140 of 184 countries worldwide (Erbil et al., 2014). In high income countries, breast cancer is about 30% cause of cancer deaths and reported to be 29% of all cancer incidences (Al-Dubai et al., 2012). There were approximately 192,000 new diagnoses of breast cancer and 47,000 deaths in the USA in 2009. Breast cancer is a major public health problem in High Income Countries as well as the Low Income countries (Yusuf et al., 2013). Previous studies revealed that the mortality rate of the

Targeted therapies in breast cancer: New challenges to fight against resistance

“…It represents the most common overexpressed receptor in breast cancers and is considered a relevant therapeutic target[59,63-69]. …”

Apoptotic effect of lambertianic acid through AMPK/FOXM1 signaling in MDA‐MB231 breast cancer cells

“…Breast cancer is known to be the most common type of cancer in women worldwide (Asif, Sultana, Ahmed, Akhtar, & Tariq, ; Zarei et al, ). Previous evidences reveal that many natural compounds induce cell death in breast cancer cells without not hurting normal cells, which is very attractive to cancer research (Millimouno, Dong, Yang, Li, & Li, ; H. Wang et al, ).…”

Compound C enhances the anticancer effect of aspirin in HER-2-positive breast cancer by regulating lipid metabolism in an AMPK-independent pathway

“…HER-2-positive breast cancer is a highly aggressive subtype of breast cancer. The number of HER-2 proteins in HER-2-positive cancer cells is approximately 2 × 10 6 ; this is about 100 times more than normal cells [2], which allow cancer cells to proliferate more rapidly. Thus, treating HER-2-positive breast cancer is quite difficult.…”

“…Breast cancer is the most common type of malignant tumor in women worldwide, and is the second leading cause of cancer-related death in females globally [1]. Human epidermal growth factor receptor-2 (HER-2) is found in approximately 30% of breast cancer patients [2]. It plays important roles in promoting breast cancer invasion and metastasis [3], and acts as an important biomarker for diagnosis and as a target for the clinical treatment of breast cancer patients.…”